Paris, May 29, 2018 – Medicen Paris Region, Europe’s leading health cluster, today announces the renewal of its governing bodies for the next three years. At the annual shareholders’ meeting on May 24, members also approved the financial statements for the year ended December 31, 2017.
On the board of directors and the executive board, the following were elected or re-elected:
- Christian Lajoux, president
- Philippe Genne, vice president SMEs
- Jean-Marc Grognet, vice president research
- Patrick Marcellin, vice president health
“With this renewed governance, Medicen is ready to face the next challenges: to generate growth, increase competitiveness, boost the region’s attractiveness and add value for our members,” said Christian Lajoux, president of Medicen Paris Region. “Our goal is for the Ile-de-France region to be recognized as one of the world leaders in the healthcare industry, with Medicen as facilitator.”
On the research and health committee, the Assistance Publique-Hôpitaux de Paris, the CEA, INSERM, the Institut Pasteur and the Paris Est Créteil University will sit on both bodies. The CNRS, the Paris 13 University, Sup’Biotech, the Paris Descartes University and the Paris Diderot University will also sit on the board of directors.
On the large companies committee, the Roche Institute, GE Healthcare and Sanofi were elected or re-elected as members of the board and of the executive board. Innothera, the International Research Institute Servier, Intersystems, Ipsen Pharma and Philips Healthcare also participate on the board.
For the SME committee, companies Bio-Modeling Systems, Bioserenity and Eukarys will participate on the executive board and the board of directors. They will be joined in this second instance by Damae Medical, IFIS, Imstar, Invectys, Metabrain Research and Pharmagest Interactive.
The Grand Orly-Seine Bièvre local public body was elected to the board of directors for the local and regional authorities committee.
The board of directors will meet on June 14 to approve the new CEO, renew the mandate of the treasurer and of the presidents of the strategic activities areas and to appoint the members of the strategic orientation committee.
About Medicen Paris Region
Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 400 companies, research centers, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, regenerative medicine and biomaterials, digital health and translational medicine. In close collaboration with local, regional and national healthcare innovation players, Medicen Paris Region aims to:
- Foster the emergence, development and funding of certified collaborative projects in the healthcare sector, in order to create economic value and jobs
- Increase the international development of innovative startups and SMEs
- Strengthen the attractiveness of the Paris region, which represents more than 50% of life sciences activity in France
Since the creation of the cluster in 2005, 68 innovative products have been launched in the imaging, medical devices and biological tools sectors. The cluster has certified 302 projects. They received funding from the French government (French Inter-Ministry Fund FUI, Structuring Projects fund), the public investment bank Bpifrance, the National Research Agency, the European Regional Development Fund, the Investments for the Future program and/or local authorities, and the Paris region. Total investment is close to €1.9 billion ($2.3bn) and €533 million ($635M) of public aid.